Bulletin
Investor Alert

New York Markets Open in:

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 25, 2021, 7:59 p.m.

/zigman2/quotes/203149337/composite

$

575.50

Change

-0.70 -0.12%

Volume

Volume 81,319

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Previous close

$ 572.36

$ 576.20

Change

+3.84 +0.67%

Day low

Day high

$569.53

$578.73

Open

52 week low

52 week high

$441.00

$686.62

Open

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accele...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Valuation

P/E Current

18.75

P/E Ratio (with extraordinary items)

10.22

P/E Ratio (without extraordinary items)

15.83

Price to Sales Ratio

6.54

Price to Book Ratio

4.69

Price to Cash Flow Ratio

21.24

Enterprise Value to EBITDA

14.35

Enterprise Value to Sales

6.44

Total Debt to Enterprise Value

0.05

Efficiency

Revenue/Employee

931,393.00

Income Per Employee

385,093.00

Receivables Turnover

2.50

Total Asset Turnover

0.53

Liquidity

Current Ratio

3.63

Quick Ratio

2.91

Cash Ratio

1.33

Profitability

Gross Margin

84.04

Operating Margin

42.09

Pretax Margin

44.84

Net Margin

41.35

Return on Assets

21.98

Return on Equity

31.77

Return on Total Capital

28.02

Return on Invested Capital

27.53

Capital Structure

Total Debt to Total Equity

24.45

Total Debt to Total Capital

19.65

Total Debt to Total Assets

15.71

Long-Term Debt to Equity

24.45

Long-Term Debt to Total Capital

19.65

Officers and Executives

Name Age Officer Since Title
Dr. P. Roy Vagelos 90 1995 Chairman
Dr. Leonard S. Schleifer 66 1988 President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos 59 1989 Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly - 1998 Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry 55 2013 Chief Financial Officer & Executive VP-Finance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/01/2021 Arthur Frederick Ryan
Director
2   Disposition at $577.27 per share. 1,154
10/01/2021 Arthur Frederick Ryan
Director
12   Disposition at $576.34 per share. 6,916
10/01/2021 Arthur Frederick Ryan
Director
4   Disposition at $575.41 per share. 2,301
10/01/2021 Arthur Frederick Ryan
Director
5   Disposition at $574.33 per share. 2,871
10/01/2021 Arthur Frederick Ryan
Director
7   Disposition at $573.54 per share. 4,014
10/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $572.32 per share. 572
10/01/2021 Arthur Frederick Ryan
Director
2   Disposition at $571.88 per share. 1,143
10/01/2021 Arthur Frederick Ryan
Director
9   Disposition at $570.37 per share. 5,133
10/01/2021 Arthur Frederick Ryan
Director
15   Disposition at $569.54 per share. 8,543
10/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $568.03 per share. 568
10/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $567.99 per share. 567
10/01/2021 Arthur Frederick Ryan
Director
10   Disposition at $566.65 per share. 5,666
10/01/2021 Arthur Frederick Ryan
Director
11   Disposition at $565.36 per share. 6,218
10/01/2021 Arthur Frederick Ryan
Director
12   Disposition at $564.47 per share. 6,773
10/01/2021 Arthur Frederick Ryan
Director
3   Disposition at $563.84 per share. 1,691
10/01/2021 Arthur Frederick Ryan
Director
4   Disposition at $562.68 per share. 2,250
10/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $560.51 per share. 560
10/01/2021 Marion McCourt
EVP Commercial
1,000   Disposition at $576.75 per share. 576,750
10/01/2021 Marion McCourt
EVP Commercial
1,000   Derivative/Non-derivative trans. at $342.93 per share. 342,930
09/15/2021 N. Anthony Coles
Director
1,174   Disposition at $664.32 per share. 779,911
09/15/2021 N. Anthony Coles
Director
905   Disposition at $663.73 per share. 600,675
09/15/2021 N. Anthony Coles
Director
3   Disposition at $662.55 per share. 1,987
09/15/2021 N. Anthony Coles
Director
3,344   Disposition at $661.56 per share. 2,212,256
09/15/2021 N. Anthony Coles
Director
448   Disposition at $660.78 per share. 296,029
09/15/2021 N. Anthony Coles
Director
300   Disposition at $659 per share. 197,700
09/15/2021 N. Anthony Coles
Director
935   Disposition at $658.65 per share. 615,837
09/15/2021 N. Anthony Coles
Director
835   Disposition at $657.53 per share. 549,037
09/15/2021 N. Anthony Coles
Director
1,400   Disposition at $656.48 per share. 919,072
09/15/2021 N. Anthony Coles
Director
403   Disposition at $655.14 per share. 264,021
09/15/2021 N. Anthony Coles
Director
800   Disposition at $653.31 per share. 522,648
09/15/2021 N. Anthony Coles
Director
1,101   Disposition at $652.95 per share. 718,897
09/15/2021 N. Anthony Coles
Director
300   Disposition at $651.36 per share. 195,408
09/15/2021 N. Anthony Coles
Director
5,039   Derivative/Non-derivative trans. at $345.47 per share. 1,740,823
09/15/2021 N. Anthony Coles
Director
6,909   Derivative/Non-derivative trans. at $380.95 per share. 2,631,983
09/14/2021 Huda Y. Zoghbi
Director
998   Disposition at $650 per share. 648,700
09/14/2021 Huda Y. Zoghbi
Director
998   Derivative/Non-derivative trans. at $391.92 per share. 391,136
09/13/2021 Michael S. Brown
Director
62   Disposition at $652.26 per share. 40,440
09/13/2021 Michael S. Brown
Director
3,712   Disposition at $651.1 per share. 2,416,883
09/13/2021 Michael S. Brown
Director
1,800   Disposition at $650.4 per share. 1,170,720
09/13/2021 Michael S. Brown
Director
838   Disposition at $649.46 per share. 544,247
09/13/2021 Michael S. Brown
Director
962   Disposition at $648.48 per share. 623,837
09/13/2021 Michael S. Brown
Director
151   Disposition at $647.58 per share. 97,784
09/13/2021 Michael S. Brown
Director
100   Disposition at $646.28 per share. 64,628
09/13/2021 Michael S. Brown
Director
100   Disposition at $645.66 per share. 64,566
09/13/2021 Michael S. Brown
Director
100   Disposition at $644.89 per share. 64,489
09/13/2021 Michael S. Brown
Director
100   Disposition at $643.49 per share. 64,349
09/13/2021 Michael S. Brown
Director
400   Disposition at $642.62 per share. 257,048
09/13/2021 Michael S. Brown
Director
100   Disposition at $641.12 per share. 64,112
09/13/2021 Michael S. Brown
Director
100   Disposition at $640.77 per share. 64,077
09/13/2021 Michael S. Brown
Director
203   Disposition at $639.2 per share. 129,757
09/13/2021 Michael S. Brown
Director
676   Disposition at $638.64 per share. 431,720
09/13/2021 Michael S. Brown
Director
200   Disposition at $637.29 per share. 127,458
09/13/2021 Michael S. Brown
Director
100   Disposition at $636.74 per share. 63,674
09/13/2021 Marc Tessier-Lavigne
Director
139   Disposition at $652.26 per share. 90,664
09/13/2021 Marc Tessier-Lavigne
Director
249   Disposition at $651.54 per share. 162,233
09/13/2021 Marc Tessier-Lavigne
Director
56   Disposition at $650.33 per share. 36,418
09/13/2021 Marc Tessier-Lavigne
Director
124   Disposition at $649.35 per share. 80,519
09/13/2021 Marc Tessier-Lavigne
Director
381   Disposition at $648.25 per share. 246,983
09/13/2021 Marc Tessier-Lavigne
Director
425   Disposition at $647.39 per share. 275,140
09/13/2021 Marc Tessier-Lavigne
Director
354   Disposition at $646.24 per share. 228,768
09/13/2021 Marc Tessier-Lavigne
Director
61   Disposition at $645.21 per share. 39,357
09/13/2021 Marc Tessier-Lavigne
Director
844   Disposition at $644.52 per share. 543,974
09/13/2021 Marc Tessier-Lavigne
Director
1,549   Disposition at $643.33 per share. 996,518
09/13/2021 Marc Tessier-Lavigne
Director
1,645   Disposition at $642.54 per share. 1,056,978
09/13/2021 Marc Tessier-Lavigne
Director
952   Disposition at $641.56 per share. 610,765
09/13/2021 Marc Tessier-Lavigne
Director
981   Disposition at $640.61 per share. 628,438
09/13/2021 Marc Tessier-Lavigne
Director
1,260   Disposition at $639.45 per share. 805,707
09/13/2021 Marc Tessier-Lavigne
Director
2,098   Disposition at $638.46 per share. 1,339,489
09/13/2021 Marc Tessier-Lavigne
Director
816   Disposition at $637.71 per share. 520,371
09/13/2021 Marc Tessier-Lavigne
Director
816   Disposition at $636.64 per share. 519,498
09/13/2021 Huda Y. Zoghbi
Director
2   Disposition at $651.1 per share. 1,302
09/13/2021 Michael S. Brown
Director
3,612   Derivative/Non-derivative trans. at $413.33 per share. 1,492,947
09/13/2021 Michael S. Brown
Director
3,613   Derivative/Non-derivative trans. at $413.33 per share. 1,493,361
09/13/2021 Michael S. Brown
Director
2,479   Derivative/Non-derivative trans. at $380.95 per share. 944,375
09/13/2021 Marc Tessier-Lavigne
Director
4,250   Derivative/Non-derivative trans. at $273.67 per share. 1,163,097
09/13/2021 Marc Tessier-Lavigne
Director
4,250   Derivative/Non-derivative trans. at $273.67 per share. 1,163,097
09/13/2021 Marc Tessier-Lavigne
Director
4,250   Derivative/Non-derivative trans. at $273.67 per share. 1,163,097
09/13/2021 Huda Y. Zoghbi
Director
2   Derivative/Non-derivative trans. at $391.92 per share. 783
09/10/2021 Joseph L. Goldstein
Director
2,479   Disposition at $650 per share. 1,611,350
09/10/2021 Joseph L. Goldstein
Director
2,479   Derivative/Non-derivative trans. at $380.95 per share. 944,375
09/01/2021 Arthur Frederick Ryan
Director
2   Disposition at $684.31 per share. 1,368
09/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $683.79 per share. 683
09/01/2021 Arthur Frederick Ryan
Director
4   Disposition at $682.32 per share. 2,729
09/01/2021 Arthur Frederick Ryan
Director
2   Disposition at $681.48 per share. 1,362
09/01/2021 Arthur Frederick Ryan
Director
4   Disposition at $680.53 per share. 2,722
09/01/2021 Arthur Frederick Ryan
Director
3   Disposition at $679.55 per share. 2,038
09/01/2021 Arthur Frederick Ryan
Director
10   Disposition at $678.43 per share. 6,784
09/01/2021 Arthur Frederick Ryan
Director
3   Disposition at $677.7 per share. 2,033
09/01/2021 Arthur Frederick Ryan
Director
21   Disposition at $676.54 per share. 14,207
09/01/2021 Arthur Frederick Ryan
Director
7   Disposition at $675.7 per share. 4,729
09/01/2021 Arthur Frederick Ryan
Director
14   Disposition at $674.51 per share. 9,443
09/01/2021 Arthur Frederick Ryan
Director
19   Disposition at $673.56 per share. 12,797
09/01/2021 Arthur Frederick Ryan
Director
10   Disposition at $672.75 per share. 6,727
09/01/2021 Marion McCourt
EVP Commercial
1,000   Disposition at $674.72 per share. 674,720
09/01/2021 Marion McCourt
EVP Commercial
1,000   Derivative/Non-derivative trans. at $342.93 per share. 342,930
08/31/2021 Robert E. Landry
EVP Finance CFO
917   Derivative/Non-derivative trans. at $675.03 per share. 619,002
08/31/2021 Robert E. Landry
EVP Finance CFO
1,000   Derivative/Non-derivative trans. at $555.67 per share. 555,670
08/30/2021 George L. Sing
Director
300   Disposition at $672 per share. 201,600
08/30/2021 George L. Sing
Director
250   Disposition at $670 per share. 167,500
08/30/2021 George L. Sing
Director
500   Disposition at $675 per share. 337,500
08/30/2021 George L. Sing
Director
500   Disposition at $670 per share. 335,000
08/27/2021 Christine A. Poon
Director
112   Disposition at $672.27 per share. 75,294
08/27/2021 Christine A. Poon
Director
1,737   Disposition at $671.49 per share. 1,166,378
08/27/2021 Christine A. Poon
Director
3,447   Disposition at $670.48 per share. 2,311,144
08/27/2021 Christine A. Poon
Director
2,235   Disposition at $669.59 per share. 1,496,533
08/27/2021 Christine A. Poon
Director
603   Disposition at $668.33 per share. 403,002
08/27/2021 Christine A. Poon
Director
2,150   Disposition at $667.37 per share. 1,434,845
08/27/2021 Christine A. Poon
Director
1,118   Disposition at $666.7 per share. 745,370
08/27/2021 Christine A. Poon
Director
538   Disposition at $665.33 per share. 357,947
08/27/2021 Christine A. Poon
Director
700   Disposition at $664.42 per share. 465,094
08/27/2021 Christine A. Poon
Director
2,260   Disposition at $663.51 per share. 1,499,532
08/27/2021 Christine A. Poon
Director
100   Disposition at $662.62 per share. 66,262
08/27/2021 Christine A. Poon
Director
15,000   Derivative/Non-derivative trans. at $57.11 per share. 856,650
08/26/2021 George L. Sing
Director
150   Disposition at $672 per share. 100,800
/news/latest/company/us/regn

MarketWatch News on REGN

  1. Don't Count Out Covid-19 Monoclonal Antibody Treatments

    11:04 a.m. Oct. 15, 2021

    - Josh Nathan-Kazis

  2. FDA Will Consider Regeneron's Covid-19 Antibody for Full Approval

    10:39 a.m. Oct. 14, 2021

    - Josh Nathan-Kazis

  3. Merck Submits Covid Pill to FDA for Emergency Approval

    8:27 a.m. Oct. 11, 2021

    - Jack Denton

  4. Merck’s Covid Pill Could Pose Serious Risks, Scientists Warn

    6:47 a.m. Oct. 8, 2021

    - Josh Nathan-Kazis

  5. Merck Says Pill Cuts Covid Hospitalization by 50%

    12:40 p.m. Oct. 1, 2021

    - Josh Nathan-Kazis

  6. Merck: Covid-19 Pill Looks Good Against Variants

    8:33 a.m. Sept. 29, 2021

    - Josh Nathan-Kazis

  7. Loading more headlines...
/news/nonmarketwatch/company/us/regn

Other News on REGN

  1. CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

    11:06 a.m. Oct. 25, 2021

    - Zacks.com

  2. Regeneron Looks Oversold, Ready To Jump Up On Catalysts

    3:11 a.m. Oct. 25, 2021

    - Seeking Alpha

  3. LabCorp (LH) to Report Q3 Earnings: What's in the Offing?

    10:32 a.m. Oct. 22, 2021

    - Zacks.com

  4. What is in Store for Bristol-Myers (BMY) in Q3 Earnings?

    10:10 a.m. Oct. 22, 2021

    - Zacks.com

  5. Biotech Buyouts That Would Be Great for Investors

    7:05 a.m. Oct. 22, 2021

    - Motley Fool

  6. Radius (RDUS) Up On Positive Data From Breast Cancer Study

    10:14 a.m. Oct. 21, 2021

    - Zacks.com

  7. Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

    6:53 a.m. Oct. 21, 2021

    - Zacks.com

  8. Loading more headlines...

At a Glance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Phone

1 9148477000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$8.50B

Net Income

$3.51B

2020 Sales Growth

8.1%

Employees

9,123

/news/pressrelease/company/us/regn

Press Releases on REGN

  1. Learn to Evaluate Regeneron Pharmaceuticals (REGN) using the Charts

    3:06 p.m. Oct. 23, 2021

    - Stock Traders Daily

  2. Why Regeneron, Intellia Therapeutics On Sale

    6:43 a.m. Oct. 14, 2021

    - Baystreet.ca

  3. Learn to Evaluate Regeneron Pharmaceuticals (REGN) using the Charts

    5:07 p.m. Oct. 13, 2021

    - Stock Traders Daily

  4. Merck Drug Shakes Up Covid-19 Market

    6:27 a.m. Oct. 5, 2021

    - Baystreet.ca

  5. Learn to Evaluate Regeneron Pharmaceuticals (REGN) using the Charts

    5:15 p.m. Oct. 2, 2021

    - Stock Traders Daily

  6. Nasdaq 100 Movers: MRNA, MAR

    12:49 p.m. Oct. 1, 2021

    - MarketNewsVideo.com

  7. S&P 500 Movers: MRNA, MRK

    12:48 p.m. Oct. 1, 2021

    - MarketNewsVideo.com

  8. Loading more headlines...
Link to MarketWatch's Slice.